Mesoblast and fda align on key items for revascor® biologic license application in ischemic heart failure

New york, june 30, 2025 (globe newswire) -- mesoblast (nasdaq:meso; asx:msb), global leader in allogeneic cellular medicines for inflammatory diseases, today announced alignment with the united states food and drug administration (fda) on items required for filing a biologics license application (bla) for revascor® (rexlemestrocel-l) in the treatment of patients with ischemic heart failure with reduced ejection fraction (hfref) and inflammation.
MESO Ratings Summary
MESO Quant Ranking